How It Works — Brokers & Consultants

Differentiate Your Benefits Portfolio

MapperHealth gives brokers and consultants a powerful, evidence-based tool to drive value for self-funded clients and win new business.

Partner With Us

For Brokers and Consultants

We strive to provide better health outcomes and reduce costs

See a Demo

MapperHealth strengthens your relationships with your existing clients and enables you to acquire new ones.

Existing Clients

MapperHealth strives to enhance the health of employees and their family members and reduce companies' total drug spend and overall healthcare costs.

New Customers

MapperHealth is clinically validated and has been shown to help control high dollar specialty spend, providing its partners a cutting-edge tool to win new business.

Differentiator

MapperHealth gives brokers a competitive edge through DNA-driven personalized medication recommendations — including RxMapper for drug optimization and DxMapper for genomic health risk reports.

Genomic Health Risk Screening

Risk That Standard Screening Can't See.

DxMapper identifies serious genomic risk across 12 conditions — delivering early awareness that is invisible to every other clinical screening method. For your clients' members, that awareness can be life-changing. For your clients' plans, it can be budget-saving.

Clinical Example

Alzheimer's Disease

APOE Variant

Without DxMapper

A 58-year-old member shows no cognitive symptoms. Standard annual labs return normal. No clinical flag is raised.

With DxMapper

APOE variant detected during genomic screening — conferring a 10.8× greater odds of Alzheimer's disease. Member is counseled, enrolled in cognitive monitoring, and connected to preventive lifestyle interventions and clinical trial eligibility years before any symptom appears.

Outcome

Early awareness. Proactive care plan. The window for meaningful intervention — open.

Odds ratio reflects published APOE ε4 homozygous risk data.

10.8× OR

Clinical Example

Venous Thromboembolism

F5 (Factor V Leiden)

Without DxMapper

A 34-year-old female employee is prescribed oral contraceptives. F5 carrier status is unknown. Six months later she is hospitalized for a pulmonary embolism — a known, avoidable complication in F5 carriers.

With DxMapper

F5 variant identified during genomic screening — conferring a 7.4× greater odds of VTE. Her physician is alerted before OCP prescription. Alternative contraception is recommended. She travels for work aware of her clot risk. No event occurs.

Outcome

Hospitalization avoided. Member healthy and at work.

Odds ratio reflects published F5 (Factor V Leiden) VTE risk data.

7.4× OR

76%of members receive at least one high-risk indication

12conditions screened across cancer, heart, brain & more

2–3×case enrichment in the preventive screening window

Learn about DxMapper →

76% figure based on DxMapper internal estimates and data. Case enrichment: Chuong et al., Nature Communications, 2026.

What We Deliver

The Broker Advantage

01 / 04

Improve Healthcare

Promotes the health and wellbeing of employees and their family members by ensuring they are on the medications most likely to work for their unique DNA.

Our Solutions Can Help

Retain existing clients, and win new clients
Save clients' money
Improve health outcomes and adherence

Interested In Learning More?

Reach out to our team to learn about our broker and consultant partner program.